Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Immunic第一季度每股收益（0.30）未達到預期（0.26）美元，截至2024年3月31日，現金及等價物爲9,730萬美元
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 48.28 percent increase over losses of $(0.58) per share from the same period last year.
Immunic（納斯達克股票代碼：IMUX）公佈的季度虧損爲每股0.30美元，比分析師普遍預期的0.26美元（0.26美元）低15.38％。這比去年同期每股虧損0.58美元（0.58美元）增長了48.28％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。